Treatment-failure gout: A moving target

Arthritis and Rheumatism

Volumn 58, Issue 9, 2008, Pages 2587-2590

  Edwards, N Lawrence ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; FUROSEMIDE; HEPARIN; MACROGOL; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; PROBENECID; SULFINPYRAZONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; URATE OXIDASE; URIC ACID;

AGING; BEER; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; EDITORIAL; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; INCIDENCE; INFLAMMATORY DISEASE; KIDNEY FAILURE; NEPHROTOXICITY; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE; URIC ACID BLOOD LEVEL;

ALLOPURINOL; CLINICAL TRIALS AS TOPIC; GOUT; GOUT SUPPRESSANTS; HUMANS; POLYETHYLENE GLYCOLS; TREATMENT FAILURE; URATE OXIDASE;

EID: 51849139524     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23803     Document Type: Editorial

References (25)

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35.
2. St-Onge MP, Keller KL, Heymsfield SB. Changes in childhood food consumption patterns: a cause for concern in light of increasing body weights. Am J Clin Nutr 2003;78:1068-73.
3. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;65:267-72.
4. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999;33:225-34.
5. Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000;43:103-8.
6. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004;363:1277-81.
7. Hahn P, Edwards NL, Management of hyperuricemia. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions: a textbook of rheumatology, 15th ed. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 2341-55.
8. Terkeltaub RA. Clinical practice: gout. N Engl J Med 2003;349:1647-55.
9. Pascual E, Sivera F. Why is gout so poorly managed? [editorial]. Ann Rheum Dis 2007;66:1269-70.
10. Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007;57:822-9.
11. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9.
12. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
13. Perez-Ruiz FC, Calabozo M, Fernandez-Lopez, MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erasukin G, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999;5:49-55.
14. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relationship between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3.
15. Gutman AB. Uricosuric drugs, with special reference to probenecid and sulfinpyrazone. Adv Pharmacol 1966;4:91-142.
16. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
17. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34.
18. Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, et al, for the Pegloticase Phase 2 Study Investigators. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-faulure gout: results of a phase II randomized study. Arthritis Rheum 2008;58:2882-91.
19. Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery C Jr, Jones P, et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci U S A 1994;91:742-6.
20. Oppenheimer EH. The lowering of blood uric acid by uricase injections. Bull Johns Hopkins Hosp 1941;68:190-5.
21. London M, Hudson PB. Uricolytic activity of purified uricase in two human beings. Science 1957;125:937-8.
22. Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008;60:59-68.
23. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat versus allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
24. Terkeltaub R, Baird S, Sears P, Santiago R, Boisvert W. The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in the air pouch model of acute crystal-induced gouty synovitis. Arthritis Rheum 1998;41:900-9.
25. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007;66:1683-4.